Harbour BioMed licenses transgenic platform to Innovent Biologics.
M2 PHARMA-October 12, 2017-Harbour BioMed licenses transgenic platform to Innovent Biologics
(C)2017 M2 COMMUNICATIONS
Global biopharmaceutical company Harbour BioMed has licensed its patented H2L2 transgenic mouse platform for generating fully human therapeutic monoclonal antibodies, to Innovent Biologics Inc, a biopharmaceutical company in China, the company announced on Thursday.
Harbour BioMed's transgenic H2L2 platform allows biotechnology and pharmaceutical companies and academic research labs to speed up new drug development through the creation of fully human antibodies.
Innovent was issued the licence via Harbour BioMed's wholly owned subsidiary, Harbour Antibodies BV. The licensing agreement stipulates that Innovent has the rights to use the H2L2 platform for multiple projects over a multi-year licensing term. In return, Harbour BioMed will receive an upfront payment, as well as fees, milestones and royalties contingent on net sales..
"The increasing adoption of our platforms reflects their power as rapid and efficient antibody discovery tools and our strong intellectual property position," said Dr Jingsong Wang, CEO of Harbour BioMed.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 12, 2017|
|Previous Article:||Philogen granted IND approval by FDA for Phase 3 registration trial with investigational melanoma drug.|
|Next Article:||Sanofi to expand vaccine manufacturing site in Val de Reuil, France.|